NCT06961604Not yet recruitingEarly phase 1
A Novel Method for Determination of Thromboembolic Stroke Origin
Source: ClinicalTrials.gov · Last updated 8 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Rupture of vulnerable carotid, vertebral, and intracranial arterial plaques results in thromboembolic stroke. Identification of these culprit lesions is an important component of post-stroke care. This study seeks to test the feasibility of NaF PET-CT to detect these plaques and alter patient care. Prior studies have shown a high degree of correlation between NaF PET+ lesions and high-risk plaque features on high resolution MRI, including mirocalcification, necrosis, and ulceration.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 6 May 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Atlantic Health System
- Diseases
- Stroke
- NCT number
- NCT06961604
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 1 Jun 2025 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Overlook Medical Center Coordinator of this site? Confirm its status | Summit | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.